1. Bristol-Myers Squibb will pay $19.5 million to settle allegations that it marketed antipsychotic drug Abilify for uses not approved by the FDA and that it violated state consumer protection laws by providing misleading information about the drug’s side effects. (Reuters)
2. AstraZeneca said it will cut 700 jobs across the U.S. by early 2017, with 120 positions expected to be eliminated from its U.S. headquarters in Fairfax, Delaware. The job cuts are specific to the U.S. commercial business. (USA Today)
3. President-elect Trump’s transition team is reportedly considering Jim O’Neill, a managing director at Mithril Capital Management, to head the FDA. O’Neill served as principal associate deputy secretary at the Department of Health and Human Services during the George W. Bush administration. (Bloomberg)
4. Six former Insys Therapeutics executives, including former CEO Michael Babich, were arrested on charges of defrauding health insurers and bribing doctors in exchange for prescribing the drugmaker’s opioid Subsys. (WSJ)
5. Biogen is expected to new release new data about its experimental Alzheimer’s drug aducanumab, showing that it slowed cognitive decline and reduced brain amyloid plaque for more than 100 patients in a clinical trial. A summary of the results was released Thursday at a medical conference in San Diego. (Boston Globe)
